FDA accepts Bristol Myers NDA for mezigdomide in multiple myeloma, sets May 13, 2027 decision date

Bristol Myers Squibb secured FDA acceptance of its NDA for mezigdomide with carfilzomib, dexamethasone in relapsed or refractory multiple myeloma. * The FDA set a PDUFA target action date of May 13, 2027. * Filing backed by Phase 3 SUCCESSOR-2 data showing median PFS 18.0 months vs. 8.3 months; HR 0.48; p<0.0001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130659BIZWIRE_USPR_____20260713_BW597234) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Bristol Myers Squibb received FDA acceptance of its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone to treat relapsed or refractory multiple myeloma. The FDA has set the PDUFA target action date for a decision on May 13, 2027. This filing is supported by Phase 3 SUCCESSOR-2 data demonstrating a median progression-free survival of 18.0 months compared to 8.3 months for the control group.

Bristol Myers Squibb secured FDA acceptance of its NDA for mezigdomide with carfilzomib, dexamethasone in relapsed or refractory multiple myeloma. * The FDA set a PDUFA target action date of May 13, 2027. * Filing backed by Phase 3 SUCCESSOR-2 data showing median PFS 18.0 months vs. 8.3 months; HR 0.48; p<0.0001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130659BIZWIRE_USPR_____20260713_BW597234) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)